Chemical genetic discovery of targets and anti-targets for cancer polypharmacology.
about
Drosophila as a Potential Model for Ocular TumorsOn the Quest of Cellular Functions of PEA-15 and the Therapeutic OpportunitiesHistone lysine demethylases in Drosophila melanogasterDrosophila at the intersection of infection, inflammation, and cancerMetabolomics and systems pharmacology: why and how to model the human metabolic network for drug discoveryFAK acts as a suppressor of RTK-MAP kinase signalling in Drosophila melanogaster epithelia and human cancer cellsComputational and experimental characterization of dVHL establish a Drosophila model of VHL syndromeP6981, An Arylstibonic Acid, Is a Novel Low Nanomolar Inhibitor of cAMP Response Element-Binding Protein Binding to DNAThe interplay between obesity and cancer: a fly viewChemical strategies for development of ATR inhibitorsThe role of Cdk5 in neuroendocrine thyroid cancerLigand-target prediction by structural network biology using nAnnoLyzeComputational and Biochemical Discovery of RSK2 as a Novel Target for Epigallocatechin Gallate (EGCG)The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective'Up with the LRRK': a phosphorylated Rab10 assay for evaluation of LRRK2 activity and inhibitor engagementSmall molecule drug screening in Drosophila identifies the 5HT2A receptor as a feeding modulation targetPolypharmacology in Precision Oncology: Current Applications and Future ProspectsRAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1Taking Stock of the Drosophila Research EcosystemCuration and analysis of multitargeting agents for polypharmacological modeling.Polypharmacology: drug discovery for the future.A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders.Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it.From a multipotent stilbene to soluble epoxide hydrolase inhibitors with antiproliferative properties.DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitorsOvercoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy.Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicityMalignant Drosophila tumors interrupt insulin signaling to induce cachexia-like wasting.Anti-cancer drug discovery: update and comparisons in yeast, Drosophila, and zebrafish.Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targetingIdentification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approachChemical genetics and regeneration.Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.CNS Anticancer Drug Discovery and Development Conference White Paper.Diverse array-designed modes of combination therapies in Fangjiomics.Drosophila Cancer Models Identify Functional Differences between Ret Fusions.The use of novel selectivity metrics in kinase research.Sorafenib inhibits p38α activity in colorectal cancer cells and synergizes with the DFG-in inhibitor SB202190 to increase apoptotic responseDREADDs for Neuroscientists.
P2860
Q26750375-4A923B24-3D79-4504-A5F2-8D01B28A5912Q26799216-070F577A-DF5A-4B2D-9FA2-B3CA7CE548E0Q26799821-27BBFB6F-B556-40F9-B7E6-3CB205F66BACQ26827570-884DC19E-9EEF-4CE9-91EB-7373EAC07A46Q27144251-F99D8FA9-8C48-4DFB-91A3-FDADA3246323Q27316587-7858DBCA-0CFE-44BF-B72F-0D4A22B93867Q27336383-99C25CDC-8518-4802-8621-0E57FFC5F3AAQ27671025-6E25626B-9BEC-4658-92B2-248EE2788853Q28079088-DA67611A-EBFE-4523-A543-2A5124CBFDDBQ28239738-0495437B-38A0-4BF8-88C1-B83D97C03442Q28392185-F4DCBA2A-DF48-48C6-B129-5A6CF748CB41Q28545126-63692105-6381-4C1C-AA8F-F34F71B1002EQ28548416-660A71F3-DBE0-47B1-8897-B29EEA9013F1Q28553277-B3913DF9-F785-4A40-A49C-10FAAD3C57A4Q28822157-458FEAFC-73EF-494B-BD51-628871008C37Q30541089-59199D5C-989D-4A7E-8E35-A73D67FB7A82Q30846907-763EBEB9-3477-4E10-B0A0-D7A3AC6E995BQ33607305-EFA1D603-48FA-4952-8DAE-F3F817F0CBBEQ33879994-7AE59C11-ABBF-46F5-944B-F58479673FA0Q34222917-C86678D4-89BD-444F-A12D-EFAEAA8FFB4CQ34319906-17AF3EA0-E72B-4820-ACA3-B7C2602F4989Q34582206-3F432EF8-62AB-48D8-8C73-6F621B27CD93Q34608239-CCA34E0C-AE27-4E1A-BAB4-79E8E0960041Q34646772-D85BCBAC-FD28-4A93-AC5E-FE40D6436D02Q34675957-6FA9A719-712C-48B1-96A3-C563B529F8E7Q34992475-FA595E25-99CF-4BD4-A63B-D8D86F99EFF2Q35016157-7336B071-AB28-4E98-B350-65D01DE60E6CQ35189855-20686C43-09A9-4245-AEA6-099F18BEE5CFQ35332991-82DD918A-A35C-4F48-8AB2-C6B35729DDB2Q35535182-5684F848-FC1D-48AF-9BBE-48277188558DQ35552376-83275587-5953-4685-B987-8540B689FC9EQ35592751-CB727A75-DDD3-4290-BA6B-ADC893A0D25AQ35825358-39440780-BE28-40D8-9C97-0CF3C9C2194AQ35951645-D6B86489-22F0-468D-8393-D28934F4260BQ36089590-D4C14553-28A5-42BA-8524-BFC812604D1CQ36123974-D45C6CCF-D09A-492B-8D41-4637C813C5BDQ36132331-1C55FFFA-9D3C-4C71-B363-150F21F41D08Q36240657-18E3E5D4-0120-4F9A-BDBE-3C6D4EADA703Q36524239-4347B89B-1C78-4FDF-8815-B10C097F1E84Q36595793-A26130BD-10B6-434A-AC48-C3B77DA15002
P2860
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology.
@en
type
label
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology.
@en
prefLabel
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology.
@en
P2093
P2860
P356
P1433
P1476
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology.
@en
P2093
Arvin C Dar
Kevan M Shokat
Ross L Cagan
Tirtha K Das
P2860
P2888
P356
10.1038/NATURE11127
P407
P577
2012-06-06T00:00:00Z
P5875
P6179
1030679391